November 6, 2025 Third Quarter 2025 Earnings Conference Call IMPORTANT NOTICES Forward-looking Statements. During the presentation, any comments made about future plans, events, financial results, performance, prospects, or growth opportunities, including statements relating to the Company's financial outlook (including, among others, Company, Topgolf and core business revenues, same venue sales, the Non-GAAP Projections (as defined below), and capital expenditures), our plans to pursue a separation of the ...

Financial Performance - GAAP Revenue for Fiscal Second Quarter 2026 was $1,140.4 million, up 6.0% QoQ and down 2.0% YoY[17] - Gross Margin for Fiscal Second Quarter 2026 was 56.7%, increased by 236 basis points QoQ[17] - Operating Margin for Fiscal Second Quarter 2026 was 24.3%, increased by 364 basis points QoQ[17] - Diluted Earnings Per Share for Fiscal Second Quarter 2026 was $0.35, increased by 29.6% QoQ[17] - Adjusted Trailing Twelve Months (TTM) EBITDA was $1,102.9 million, representing 26.2% of TTM sales[17] - Adjusted Free Cash Flow was $38.3 million, representing 3.4% of net sales[17] Capital Allocation - The company paid $245.8 million in common dividends[17] - The company announced a common stock dividend of 45.5 cents per share for Q3FY26[17] - The company has reduced debt 24 out of the last 29 quarters[46] - The company has paid dividends for 92 consecutive quarters[46]

Financial Performance - Revenue decreased to $536 million in Q3 2025, compared to $629 million in Q3 2024 [17], primarily due to the cessation of concentrate sales in Q2, offset by increased sales of separated products and magnetic precursor products [15] - Adjusted EBITDA was negative $126 million in Q3 2025, compared to negative $112 million in Q3 2024 [17], impacted by the cessation of concentrate sales, offset by EBITDA contribution from Magnetics and improved per-unit production costs of separated products [15] - Adjusted Diluted EPS was negative $010 in Q3 2025, compared to negative $012 in Q3 2024 [17], driven by a higher tax benefit and higher interest income, partially offset by higher depreciation expense [15] Operational Metrics (Materials Segment) - REO production volumes increased slightly to 13,254 MT in Q3 2025 from 13,145 MT in Q2 2025 [21] - NdPr production reached a record of 721 MT in Q3 2025, a 21% sequential increase [14] - NdPr sales volumes increased to 525 MT in Q3 2025 from 443 MT in Q2 2025 [21] Segment Performance - Materials segment revenue was $316 million in Q3 2025, down from $629 million in Q3 2024 [24], due to the cessation of concentrate sales [23] - Magnetics segment revenue was $219 million in Q3 2025 [24], driven by initial production and sales of magnetic precursor products at Independence [23] - Materials segment Adjusted EBITDA was negative $145 million in Q3 2025, compared to negative $26 million in Q3 2024 [24], impacted by the cessation of concentrate sales [23] - Magnetics segment Adjusted EBITDA improved to $95 million in Q3 2025 [24], driven by ramp of magnetic precursor product sales [23] Strategic Initiatives - The Department of War (DoW) purchase price agreement commenced on October 1, 2025 [14] - Initial Apple prepayment of $40 million was received [14]

Company Strategy & Focus - Amphastar operates with a "Three-H" focus: High Quality, High Efficiency, and High Technology, aiming for high net income margins[8, 15, 17] - The company employs a dual-strategy growth model, combining organic pipeline development with strategic acquisitions[8, 13, 14] - Amphastar is strategically shifting its pipeline towards proprietary products and biosimilars, projecting a change from 63% generic, 16% biosimilar, and 21% proprietary in 2021 to 15% generic, 35% biosimilar, and 50% proprietary in 2026[19, 20] Financial Performance & R&D Investment - Amphastar's revenue has grown steadily, reaching $732 million in 2024[15, 47] - Adjusted net income margin has increased significantly, reaching 27.4% in 2024[15, 16] - The company has invested approximately $351 million in self-funded R&D over the recent 5 years[26] Pipeline & Product Portfolio - Key pipeline products include AMP-002 (Iron Sucrose), with +$500 million in IQVIA sales and AMP-017 (Inhalation) with +$1.3 billion in IQVIA sales[29] - The company has an interchangeable insulin pipeline covering the full spectrum of insulin, targeting a $4.5 billion market[31, 32] - Amphastar in-licensed three new peptide assets (AMP-105, -107, -109) targeting oncology and ophthalmology, with a combined market potential exceeding $60 billion[34, 37] Key Products & Sales - BAQSIMI® sales are projected to reach a peak of $250 million to $275 million, with an estimated $2.00 to $2.50 incremental adjusted EPS at peak[54, 59] - Primatene MIST® annual sales reached $102 million in 2024, with forecasts of high single-digit growth in 2025[61, 62]

Financial Performance - Originations reached $6.5 billion in funded volume[17] - Total revenue was $323.3 million on $7.0 billion of pull-through weighted lock volume[17] - Adjusted revenue amounted to $325.2 million[19] - The company experienced an adjusted net loss of $2.8 million and an adjusted EBITDA of $48.8 million[17] - Unrestricted cash stood at $459 million[19] Operational Highlights - The servicing portfolio increased to $118.2 billion[17] - The organic refinance consumer direct recapture rate was 65%[17] - Purchase mix accounted for 60% of originations[19] - The company serves approximately 440,000 clients[10] Outlook - Q4 2025 pull-through weighted rate lock volume is projected to be between $6.0 billion and $8.0 billion[44] - Q4 2025 origination volume is expected to range from $6.5 billion to $8.5 billion[44]

Financial Performance - Revenue reached $479.5 million, reflecting an 8% sequential increase, driven by new launches in Performance Suite and Specialty Tech & Services[6] - Adjusted EBITDA was $39.0 million, a 23% year-over-year growth[6] - The company narrowed its revenue outlook for 2026 to between $1.87 billion and $1.88 billion[6] - Adjusted EBITDA outlook narrowed to between $144 million and $154 million[6] Capital Allocation - Evolent Health had $116.7 million in cash and cash equivalents as of September 30, 2025, with $47.5 million in revolver availability[6] - The company issued $166.8 million of 4.50% 2031 Notes and repaid $167.4 million of 2025 Notes[6] - Evolent repurchased 4.4 million shares of common stock for $40.0 million[6] - Exchanged $175.0 million of Series A Preferred Stock for second lien term loan on similar terms, with interest now tax deductible[6] - Period-end net leverage was 6.7x on LTM Adjusted EBITDA of $136.0 million[6] Business Growth - Announced two new revenue arrangements, one in the Performance Suite and one in the Technology and Services Suite, bringing YTD total to 13, forecasting approximately $2.5 billion for 2026[6]

Q3 2025 Financial Performance - Revenue for Q3 2025 was $634.5 million, compared to $687.5 million in Q3 2024, a decrease of 7.7%[9] - Gross profit for Q3 2025 was $184.4 million, with a gross margin of 29.1%, compared to $213.1 million and 31.0% respectively in Q3 2024[9] - Operating income for Q3 2025 was $47.6 million, resulting in an operating margin of 7.5%, compared to $22.3 million and 3.2% respectively in Q3 2024[9] - Net income for Q3 2025 was $29.3 million, or $0.76 per share, compared to $7.0 million, or $0.18 per share in Q3 2024[9] - Adjusted EBITDA for Q3 2025 was $57.5 million, with an adjusted EBITDA margin of 9.1%, compared to $73.9 million and 10.7% respectively in Q3 2024[9] Segment Performance - Nurse & Allied Solutions revenue was $361 million in Q3 2025, a 9.5% decrease year-over-year[9] - Physician & Leadership Solutions revenue was $175 million in Q3 2025, a 1.3% decrease year-over-year[9] - Technology & Workforce Solutions revenue was $95 million in Q3 2025, an 11.8% decrease year-over-year[9] Balance Sheet and Cash Flow - Cash and cash equivalents totaled $53 million as of September 30, 2025, compared to $42 million as of June 30, 2025[35] - Net cash provided by operating activities was $23 million in Q3 2025, compared to $67 million in Q3 2024[37] - Free cash flow was $15 million in Q3 2025, compared to $47 million in Q3 2024[37] Q4 2025 Financial Guidance - Consolidated revenue is projected to be between $715 million and $730 million[39] - Gross margin is expected to be between 25.5% and 26.0%[39] - Adjusted EBITDA margin is projected to be between 6.8% and 7.3%[39]

Century Aluminum Company 3 rd Quarter Earnings Call November 6, 2025 Cautionary Statement Certain statements in this presentation, and those made by Century Aluminum Company management on the quarterly conference call, relate to future events and expectations and are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "believe," "expect," "hope," "target," "anticipate," "intend," "plan," "seek," "estimate," "potential," "project," "scheduled ...

FiscalNote Powering Better Policy Decisions with AI-Driven Insights CORPORATE OVERVIEW November 6, 2025 © 2025 FiscalNote fiscalnote.com Footnote: Unless otherwise indicated, data presented herein is as of September 30, 2025. 1 Safe Harbor Statement Safe Harbor Statement Certain statements herein may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or FiscalNote's future financial ...

FINANCIAL RESULTS: Q3:2025 SLIDE SUPPLEMENT • Welcome • Business Highlights and Updates Stephen Gunstream, President and Chief Executive Officer • Financial Results and 2025 Outlook Matt Lowell, Chief Financial Officer • Q&A Forward-looking statements and use of non-GAAP financial measures Statements in this presentation about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute "forward-looking statements." These statemen ...